Citadel Advisors
SIOX

Citadel Advisors’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Citadel Advisors’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,600
Closed -$696 – 16041
2022
Q4 		$696 Buy
+1,600
New +$519 ﹤0.01% 14600
2022
Q3 		– Sell
-14,000
Closed -$5K – 14049
2022
Q2 		$5K Sell
14,000
-10,700
-43% -$4.43K ﹤0.01% 12684
2022
Q1 		$17K Sell
24,700
-12,400
-33% -$10.5K ﹤0.01% 13294
2021
Q4 		$48K Buy
37,100
+17,300
+87% +$30.7K ﹤0.01% 13279
2021
Q3 		$43K Sell
19,800
-26,600
-57% -$57.8K ﹤0.01% 13445
2021
Q2 		$127K Buy
46,400
+23,600
+104% +$58.7K ﹤0.01% 12687
2021
Q1 		$60K Sell
22,800
-500
-2% -$1.41K ﹤0.01% 12810
2020
Q4 		$65K Sell
23,300
-5,200
-18% -$15.1K ﹤0.01% 10465
2020
Q3 		$132K Buy
28,500
+15,000
+111% +$49.5K ﹤0.01% 9096
2020
Q2 		$38K Sell
13,500
-2,000
-13% -$6.42K ﹤0.01% 9408
2020
Q1 		$38K Buy
15,500
+3,600
+30% +$13K ﹤0.01% 9134
2019
Q4 		$61K Sell
11,900
-13,900
-54% -$77.1K ﹤0.01% 8701
2019
Q3 		$167K Sell
25,800
-2,100
-8% -$14.5K ﹤0.01% 8246
2019
Q2 		$174K Buy
27,900
+18,412
+194% +$140K ﹤0.01% 8278
2019
Q1 		$101K Sell
9,488
-125
-1% -$1.25K ﹤0.01% 8555
2018
Q4 		$77K Sell
9,613
-1,937
-17% -$27.9K ﹤0.01% 8360
2018
Q3 		$224K Buy
11,550
+237
+2% +$4.31K ﹤0.01% 8040
2018
Q2 		$205K Buy
11,313
+7,538
+200% +$111K ﹤0.01% 7852
2018
Q1 		$40K Sell
3,775
-3,488
-48% -$56K ﹤0.01% 7988
2017
Q4 		$306K Buy
7,263
+3,163
+77% +$142K ﹤0.01% 6434
2017
Q3 		$226K Sell
4,100
-4,700
-53% -$793K ﹤0.01% 6512
2017
Q2 		$1.63M Buy
8,800
+412
+5% +$72.2K ﹤0.01% 3434
2017
Q1 		$1M Buy
8,388
+6,888
+459% +$722K ﹤0.01% 3990
2016
Q4 		$149K Sell
1,500
-2,425
-62% -$255K ﹤0.01% 6512
2016
Q3 		$440K Buy
+3,925
New +$471K ﹤0.01% 5048
2016
Q1 		– Sell
-1,738
Closed -$251K – 8289
2015
Q4 		$251K Sell
1,738
-275
-14% -$35.8K ﹤0.01% 5487
2015
Q3 		$208K Buy
+2,013
New +$236K ﹤0.01% 6092

Other funds holding SIOX

JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

Citadel Advisors's SIOX Position: Q1 2023 in Review

Citadel Advisors sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2023, closing a stake of 15,202 shares — an estimated $6.61K sold.

Citadel Advisors first reported a position in SIOX in Q2 2015 and held it in 28 quarters. The position peaked at $9.28M in Q1 2017. 4 funds tracked by Wall St. Rank hold SIOX as of Q1 2023.

  • Citadel Advisors reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Citadel Advisors sold 15,202 Sio Gene Therapies Inc. Common Stock shares in Q1 2023, an estimated $6.61K.
  • Citadel Advisors first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2015 and held it in 28 quarters.
  • Citadel Advisors's Sio Gene Therapies Inc. Common Stock position peaked at $9.28M in Q1 2017.
  • 4 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.